ABC | Volume 113, Nº4, October 2019

Original Article Şahiner et al LAA occlusion with amulet device Arq Bras Cardiol. 2019; 113(4):712-721 Table 1 – Baseline Characteristics and LAA Occlusion Indications Baseline Characteristics n = 60 Mean Age 72.3 years ± 20.1 years Female Gender, n (%) 35 (58.3%) Hypertension, n (%) 56 (93.3%) Diabetes Mellitus, n (%) 22 (36.6%) Heart Failure, n (%) 23 (38.3%) Cerebrovascular Event, n (%) 17 (28.3%) Ischemic, n (%) 13 (21.6%) Hemorrhagic, n (%) 3 (5.0%) Ischemic and hemorrhagic, n (%) 1 (1.6%) Chronic Kidney Disease, n (%) 29 (48.3%) Stage 3 (GFR: 30% ≤ 59%) 14 (23.3%) Stage 4 (GFR: 15% ≤ 29%) 7 (11.6%) Stage 5 (GFR: ≤ 14%) 8 (13.3%) Atherosclerotic Heart Disease, n (%) 40 (66.7%) Peripheric Artery Disease, n (%) 7 (11.6%) Atrial Fibrillation Paroxysmal, n (%) 13 (21.6%) Persistent, n (%) 47 (78.3%) Preprocedural Anticoagulation Yes, n (%) 57 (95.0%) Rivaroxaban, n (%) 30 (50.0%) Warfarin, n (%) 4 (6.6%) Dabigatran, n (%) 10 (16.7%) Apixaban, n (%) 13 (21.7%) Follow Up, mean months ± SD, (median months, 1 st and 3 rd quartile) 21 ± 15 months (20 months, interquartile range of 9 to 27 months) Left Atrial Appendage Occlusion Indications Major bleeding, n (%) 53 (88.3%) Gastrointestinal, n (%) 36 (60.0%) Hemoptysis, n (%) 11 (18.3%) Hemorrhagic SVE, n (%) 4 (6.6%) Pericardial, n (%) 1 (1.7%) Retroperitoneal, n (%) 1 (1.7%) Chronic Kidney Disease and Labile INR, n (%) 4 (6.6%) Idiopathic Thrombocytopenic Purpura, n (%) 1 (1.7%) Cerebral Angiopathy, n (%) 1 (1.7%) Bronchiectasis, n (%) 1 (1.7%) Thromboembolic and Bleeding Risk Scores CHADS 2 mean ± SD 2.75 ± 2.25 CHA 2 DS 2 -VASc mean ± SD 4.61 ± 2.61 HASBLED mean ± SD 4.32 ± 3.32 ORBIT mean ± SD 4.8 ± 2.8 715